AmberJean P. Hansen, MPH, CCRP
she/her/hers
Research Associate 2 HSSCards
About
Research
Publications
Featured Publications
Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023
Chard A, Dalton A, Diallo A, Moulia D, Deputy N, Zecca I, Quilter L, Kachur R, McCollum A, Rowlands J, Britton A, Fisher R, Chai S, Licherdell E, Still W, Morris A, Castilho J, Markus T, Morrow A, Danza P, Hansen A, Ali S, Wegner C, Weber R, Betancourt G, Zipprich J, Sutton M, Pathela P, Hawkins S, Wendel K, Feldstein L. Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023. MMWR Morbidity And Mortality Weekly Report 2024, 73: 896-902. PMID: 39388387, PMCID: PMC11466375, DOI: 10.15585/mmwr.mm7340a2.Peer-Reviewed Original ResearchConceptsCondomless receptive anal sexReceptive anal sexAnal sexUnited StatesCase-patientsControl patientsAssociated with sexual contactSex practicesSexually active personsTransgenderAssociated with transmissionSexual contactAdjusted oddsMSMMenVaccination coverageActive personsNonintimatesVaccinePatientsMPOXVaccine promotionMultifaceted approachSexIntimateBarriers to the Uptake of Tickborne Disease Prevention Measures: Connecticut, Maryland 2016-2017
Hansen A, Wilkinson M, Niesobecki S, Rutz H, Meek J, Niccolai L, Hinckley A, Hook S. Barriers to the Uptake of Tickborne Disease Prevention Measures: Connecticut, Maryland 2016-2017. Journal Of Public Health Management And Practice 2024, 31: e52-e60. PMID: 39321400, DOI: 10.1097/phh.0000000000002033.Peer-Reviewed Original ResearchPersonal safety concernsPreventive measuresBarriers to consistent usePublic health programsLogistic regression modelsHealth programsTickborne diseasesDisease prevention measuresDemographic variablesPrimary barrierOutdoor activitiesTick checksDescriptive analysisOnline surveyRegression modelsSafety concernsCost concernsNatural pesticidesIncreased uptakePreventionBarriersTick habitatsSurveyConnecticutConcernsEstimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory CommitteeEarly Release - Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016 - Volume 28, Number 6—June 2022 - Emerging Infectious Diseases journal - CDC
Hook S, Jeon S, Niesobecki S, Hansen A, Meek J, Bjork J, Dorr F, Rutz H, Feldman K, White J, Backenson P, Shankar M, Meltzer M, Hinckley A. Early Release - Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016 - Volume 28, Number 6—June 2022 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2022, 28: 1170-1179. PMID: 35608612, PMCID: PMC9155891, DOI: 10.3201/eid2806.211335.Peer-Reviewed Original ResearchConceptsTotal societal costsSocietal costsLyme diseasePatient costsInfectious Diseases journal - CDCMean patient costMean societal costLyme disease endemic stateTotal patient costsCost-effectiveness analysisDisseminated diseaseProspective studyEarly diagnosisIncidence areaDiseaseEffective preventionProbable diseaseDemographic factorsPrevention methodsComprehensive economic evaluationEconomic evaluationPatientsVaccineIllnessDiagnosisEvaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States
Hook SA, Hansen AP, Niesobecki SA, Meek JI, Bjork JKH, Kough EM, Peterson MS, Schiffman EK, Rutz HJ, Rowe AJ, White JL, Peel JL, Biggerstaff BJ, Hinckley AF. Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. Vaccine 2021, 40: 298-305. PMID: 34895785, PMCID: PMC11705932, DOI: 10.1016/j.vaccine.2021.11.065.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineSurvey-weighted descriptive statisticsMultivariable multinomial logistic regression modelsCross-sectional studyLyme disease incidenceHigh incidence areaCross-sectional surveyLogistic regression modelsSafety concernsMultinomial logistic regression modelsVaccine uptakeAdults 45Vaccine parametersVaccine candidatesVaccine attitudesPrevention optionsHealthcare providersWeb-based surveyVaccineSociodemographic characteristicsIncidence areaLyme diseaseDisease incidenceIncidenceInterim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021
Pilishvili T, Fleming-Dutra K, Farrar J, Gierke R, Mohr N, Talan D, Krishnadasan A, Harland K, Smithline H, Hou P, Lee L, Lim S, Moran G, Krebs E, Steele M, Beiser D, Faine B, Haran J, Nandi U, Schrading W, Chinnock B, Henning D, LoVecchio F, Nadle J, Barter D, Brackney M, Britton A, Marceaux-Galli K, Lim S, Phipps E, Dumyati G, Pierce R, Markus T, Anderson D, Debes A, Lin M, Mayer J, Babcock H, Safdar N, Fischer M, Singleton R, Chea N, Magill S, Verani J, Schrag S, Team V, Team V, Yousaf A, Chung Y, Onukwube J, Xing W, Clinansmith B, Uribe L, Poronsky K, Hashimoto D, Bahamon M, St. Romain M, Kean E, Stubbs A, Roy S, Volturo G, Galbraith J, Crosby J, Fuentes M, Mulrow M, Lee J, Johnston H, Hansen A, Fridkin S, Wilson L, Lovett S, Christian M, Myers C, Ocampo V, Talbot K, Seidelman J, Milstone A, Hayden M, Samore M, Kwon J, Shirley D, Dillard D, Dobson J. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021. MMWR Morbidity And Mortality Weekly Report 2021, 70: 753-758. PMID: 34014909, PMCID: PMC8136422, DOI: 10.15585/mmwr.mm7020e2.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineVaccine effectivenessCOVID-19 vaccineHealth care personnelTest-negative case-control studyEffectiveness of mRNA COVID-19 vaccinesModerna COVID-19 vaccineCase-control studyU.S. sitesSingle doseSymptomatic diseaseClinical trialsPfizer-BioNTechSymptomatic illnessExposure to SARS-CoV-2Immunization PracticesInterim analysisHigh riskObservational studyCare personnelSpread of infectionCOVID-19 vaccine effectivenessSARS-CoV-2VaccineMedical conditionsKnowledge, attitudes, and behaviors regarding tick-borne disease prevention in endemic areas
Niesobecki S, Hansen A, Rutz H, Mehta S, Feldman K, Meek J, Niccolai L, Hook S, Hinckley A. Knowledge, attitudes, and behaviors regarding tick-borne disease prevention in endemic areas. Ticks And Tick-borne Diseases 2019, 10: 101264. PMID: 31431351, PMCID: PMC10948045, DOI: 10.1016/j.ttbdis.2019.07.008.Peer-Reviewed Original ResearchConceptsEndemic areasPrevalence of LDPrevention behaviorsShowering/bathingTick checksDisease preventionPerceived PrevalenceLyme disease vaccineLD endemic areasInsect repellentSelf-rated knowledgeUnadjusted analysesOdds ratioMultivariable modelFemale genderLD vaccineDisease vaccinePrevention optionsLocal prevalencePreventive behaviorsSociodemographic characteristicsPrevalenceMajority of respondentsOnly factorTick controlA US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction.
Rhodes JC, Kahn R, Bolcen S, Shang N, Chung Y, Farley MM, Britton AN, Moore AE, Thomas S, Nadle J, Amsden LB, Skarbinski J, VanWinden KR, Barnes M, Engesser K, Ferrieri P, Hansen AP, Harrison LH, Jeffrey L, Nyholm JL, O'Leary ST, Olson-Chen C, Rowlands JV, Seopaul SA, Thomas AR, Wrigley HHN, McGee L, Vishwanathan SA, Akhter F, Alston B, Jia LT, Li Y, Patel PY, Rivers J, Southwell JE, Tran T, Maniatis P, Schrag SJ. A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction. Nat Commun 2025, 16: 9381. PMID: 41130982, DOI: 10.1038/s41467-025-64324-y.Peer-Reviewed Original Research
2023
Operational Considerations for Using Deer-Targeted 4-Poster Tick Control Devices in a Tick-borne Disease Endemic Community
Hornbostel V, Meek J, Hansen A, Niesobecki S, Nawrocki C, Hinckley A, Connally N. Operational Considerations for Using Deer-Targeted 4-Poster Tick Control Devices in a Tick-borne Disease Endemic Community. Journal Of Public Health Management And Practice 2023, 30: 111-121. PMID: 37566802, PMCID: PMC10840788, DOI: 10.1097/phh.0000000000001809.Peer-Reviewed Original ResearchConceptsEndemic areasFuture public health interventionsPublic health interventionsDisease-endemic areasPublic health agenciesEndemic communitiesHealth interventionsCommunity settingsCommunity-wide approachEffectiveness studiesMonthly costHealth agenciesTick-borne diseasesLone star tickPersonal protectionAcceptability of 4-poster deer treatment devices for community-wide tick control among residents of high Lyme disease incidence counties in Connecticut and New York, USA
Nawrocki C, Piedmonte N, Niesobecki S, Rowe A, Hansen A, Kaufman A, Foster E, Meek J, Niccolai L, White J, Backenson B, Eisen L, Hook S, Connally N, Hornbostel V, Hinckley A. Acceptability of 4-poster deer treatment devices for community-wide tick control among residents of high Lyme disease incidence counties in Connecticut and New York, USA. Ticks And Tick-borne Diseases 2023, 14: 102231. PMID: 37531890, PMCID: PMC10883357, DOI: 10.1016/j.ttbdis.2023.102231.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
310 Cedar Street, PO Box 208063
New Haven, CT 06510
United States